Skip to content

Released Mar 14, 2019, after the close

10-K filed Mar 14, 2019, 73 days after period end · 0001564590-19-007805

Q4 2018 · 10-K
Revenue$1.69M+70.4% vs Q4 2017+157.1% vs Q3 2018
Net Income-$10.60MN/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.60N/M vs Q4 2017N/M vs Q3 2018
Operating Incomederived-$11,084,000N/M
Operating Cash Flowderived-$13,509,000N/M
Free Cash Flowderived-$15,923,000—
Margins · derived
Operating margin-655.1%+754.8 pt vs Q4 2017
Net margin-626.4%+769.6 pt vs Q4 2017

What the release said

The release

Same quarter

MetricQ4 2018Q4 2017Q4 2016
Revenue$1.69M$993.00K—
Net Income-$10.60M-$13.86M-$7.21M
EPS Diluted-$0.60-$1.59-$25.68

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR